# US 2013/0251679 A1 · Long lasting drug formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251679 A1
- Document ID: US20130251679A1
- Status: Published application
- Kind: A1
- Application number: 13/776,745
- Filed: 2013-02-26
- Published: 2013-09-26
- Earliest claimed: 2010-06-15
- Assignees: Medgenics Medical Israel Ltd.
- Applicants: Medgenics Medical Israel Ltd.
- Inventors: ANDREW PEARLMAN; BARUCH S. STERN
- Web page: https://patentgrep.com/patent/US20130251679A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/212: {IFN-alpha}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61P 7/06: Antianaemics
- C07K 14/505: Erythropoietin [EPO]
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.

## Claims

### Claim 1

A method of treating anemia in a human subject in need over a sustained time period comprising the steps of:
a. providing at least one genetically modified micro-organ that expresses and secretes erythropoietin, said micro-organ comprising a helper-dependent adenovirus vector comprising a nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid encoding erythropoietin operably linked to one or more regulatory sequences comprises SEQ ID No. 11;
b. determining erythropoietin secretion levels of said at least one genetically modified micro-organ in vitro;
c. implanting said at least one genetically modified micro-organ in said human subject at an effective dosage; and
d. measuring hemoglobin levels in the blood of said subject;
wherein the measured hemoglobin levels in said subject are maintained at 9-11 g/dl in at least 50% of the measurements for at least one month.

### Claim 2 (depends on 1)

The method of claim 1, wherein said at least one genetically modified micro-organ is a genetically modified dermal micro-organ.

### Claim 3 (depends on 1)

The method of claim 1, wherein said effective dosage is 18-150 U erythropoietin/Kg body weight of said subject/day.

### Claim 4 (depends on 3)

The method of claim 3, wherein said effective dosage is 18-30 U erythropoietin/Kg body weight of said subject/day.

### Claim 5 (depends on 3)

The method of claim 3, wherein said effective dosage is 30-50 U erythropoietin/Kg body weight of said subject/day.

### Claim 6 (depends on 3)

The method of claim 3, wherein said effective dosage is 50-65 U erythropoietin/Kg body weight of said subject/day.

### Claim 7 (depends on 3)

The method of claim 3, wherein said effective dosage is determined based on:
a. said subject's weight;
b. said subject's historical hemoglobin levels; and
c. the average amount of erythropoietin administered to said subject in the one month prior said implanting step.

### Claim 8 (depends on 1)

The method of claim 1, wherein said measured hemoglobin levels are 9-11 g/dl in at least 50% of the measurements for at least six months.

### Claim 9 (depends on 1)

The method of claim 1, further comprising a step of implanting at a later date to said subject, at least one additional genetically modified micro-organ that expresses and secretes erythropoietin, said micro-organ comprising a helper-dependent adenovirus vector comprising a nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences.

### Claim 10 (depends on 9)

The method of claim 9, wherein said nucleic acid encoding erythropoietin operably linked to one or more regulatory sequences comprises SEQ ID No. 11.

### Claim 11 (depends on 1)

The method of claim 1, further comprising a step of maintaining said at least one genetically modified micro-organ in vitro for at least 9 days, prior to said implantation step.

### Claim 12 (depends on 1)

The method of claim 1, wherein said implanting is subcutaneous or intradermal or subdermal.

### Claim 13 (depends on 1)

The method of claim 1, wherein said subject is selected from a group consisting of:
a. a subject suffering from: renal failure, chronic renal failure, chemotherapy induced anemia, anemia as a result of HIV treatments, microangiopathic haemolytic anemia, anemia as a result of prematurity, an inflammatory condition including rheumatoid arthritis, an infection, anemia associated with cancers including multiple myeloma and non-Hodgkin lymphoma, hematopoietic stem cell disorders, sickle cell anemia or thalassemia; and
b. a subject in need of accelerated erythroid repopulation after bone marrow transplantation;
or any combination thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein said subject suffering from chronic renal failure is suffering from chronic kidney disease (CKD) or end stage renal disease (ESRD).

### Claim 15

A method of increasing or maintaining physiological hemoglobin levels in a human subject over a sustained period of time comprising the steps of:
a. providing at least one genetically modified micro-organ that expresses and secretes erythropoietin, said micro-organ comprising a helper-dependent adenovirus vector comprising a nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid encoding erythropoietin operably linked to one or more regulatory sequences comprises SEQ ID No. 11;
b. determining erythropoietin secretion levels of said at least one genetically modified micro-organ in vitro;
c. implanting said at least one genetically modified micro-organ in said subject at an effective dosage; and
d. measuring hemoglobin levels in the blood of said subject,
wherein said increased or maintained physiological hemoglobin levels in said subject are maintained at 9-11 g/dl in at least 50% of the measurements for at least one month.

### Claim 16 (depends on 15)

The method of claim 15, wherein said at least one genetically modified micro-organ is a genetically modified dermal micro-organ.

### Claim 17 (depends on 15)

The method of claim 15, wherein said effective dosage is 18-150 U erythropoietin/Kg body weight of said subject/day.

### Claim 18 (depends on 17)

The method of claim 17, wherein said effective dosage is 18-30 U erythropoietin/Kg body weight of said subject/day.

### Claim 19 (depends on 17)

The method of claim 17, wherein said effective dosage is 30-50 U erythropoietin/Kg body weight of said subject/day.

### Claim 20 (depends on 17)

The method of claim 17, wherein said effective dosage is 50-65 U erythropoietin/Kg body weight of said subject/day.
